Lung Cancer
Volume 72, Issue 1 , Pages 52-58 , April 2011

Uptake and tolerance of adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada

  • Marcy Winget

      Affiliations

    • Cancer Care, Alberta Health Services, 10123-99 Street, Suite 1500, Edmonton, Alberta, T5J 3H1 Canada
    • University of Alberta, School of Public Health, 3-12 University Terrace, 8303-112 Street, Edmonton, Alberta, T6G 2T4 Canada
    • Corresponding Author InformationCorresponding author at: 10123-99 Street, Suite 1500, Edmonton, Alberta, T5J 3H1 Canada. Tel.: +1 780 643 4365; fax: +1 780 643 4486.
    • ,
  • John Fleming

      Affiliations

    • Cancer Care, Alberta Health Services, 10123-99 Street, Suite 1500, Edmonton, Alberta, T5J 3H1 Canada
    • ,
  • Xue Li

      Affiliations

    • Cancer Care, Alberta Health Services, 10123-99 Street, Suite 1500, Edmonton, Alberta, T5J 3H1 Canada
    • ,
  • Zhiwei Gao

      Affiliations

    • University of Alberta, School of Public Health, 3-12 University Terrace, 8303-112 Street, Edmonton, Alberta, T6G 2T4 Canada
    • ,
  • Charles Butts

      Affiliations

    • Cancer Care, Alberta Health Services, 10123-99 Street, Suite 1500, Edmonton, Alberta, T5J 3H1 Canada

Received 9 April 2010 ,Revised 29 June 2010 ,Accepted 11 July 2010.

References 

  1. American Cancer Society . Cancer facts & figures. 2009;
  2. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:234S–242S
  3. Fry W, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States. A National Cancer Data Base Report. Cancer. 1999;86:1867–1876
  4. Winton T, Livingston R, Johnson D, Rigas J, Johnson M, Butts C, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597
  5. Douillard JY, Rosell R, De Lena M, Carpagnano F, Ramlau R, Gonzáles-Larriba JL, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7:19–27
  6. Arriagada R, Bergman B, Dunant A, Le CT, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360
  7. Winget M, Stanger J, Gao Z, Butts C. Predictors of surgery and consult with an oncologist for adjuvant chemotherapy in early stage NSCLC patients in Alberta, Canada. J Thorac Oncol. 2009;4:629–634
  8. Standards for Cancer Registries Volume II: Data Standards and Data Dictionary, Record Layout Version 12. Springfield, IL: North American Association of Central Cancer Registries; 2009;
  9. Deddens JA, Peterson MR. Approaches for estimating prevalence ratios. Occup Environ Med. 2008;65:501–506
  10. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. New York: Springer; 2001;
  11. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst. 2001;93:850–857
  12. Ayanian JZ, Zaslavsky AM, Fuchs CS, Guadagnoli E, Creech CM, Cress RD, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–1300
  13. Cree M, Tonita J, Turner D, Nugent Z, Alvi R, Barss R, et al. Comparison of treatment received versus long-standing guidelines for stage III colon and stage II/III rectal cancer patients diagnosed in Alberta, Saskatchewan and Manitoba in 2004. Clin Colorectal Cancer. 2009;8(3):141–145
  14. Winget M, Hossain S, Yasui Y, Scarfe A. Characteristics of stage III colon adenocarcinoma patients who fail to receive guideline-recommended treatment. Cancer, doi:10.1002/cncr.25250 [published online in advance of print 24 June 2010].
  15. Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ , et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. 2006 ASCO annual meeting proceedings, Part I. J Clin Oncol. 2006;24(18S):7008
  16. Strauss GM, Herndon JE, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant chemotherapy in stage IB non-small cell lung cancer (NSCLC): update of Cancer and Leukemia Group B (CALGB) protocol 9633. 2006 ASCO annual meeting proceedings, Part I. J Clin Oncol. 2006;24(18S):7007
  17. Pisters KMW, Evans WK, Azzoli CG, Kris MG, Smith CA, Desch CE, et al. Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I–IIIA Resectable Non-Small Cell Lung Cancer Guideline. J Clin Oncol. 2007;25(24):1–13
  18. Langer CJ, Manola J, Bernardo P, Kugler JW, Bonomi P, Cella D, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173–181
  19. Rocha Lima CM, Herndon JE, Kosty M, Clamon G, Green MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002;94:181–187
  20. Alam N, Shepherd FA, Winton T, Graham B, Johnson D, Livingston R, et al. Compliance with post-operative adjuvant chemotherapy in non-small cell lung cancer: an analysis of National Cancer Institute of Canada and intergroup trial JBR.10 and a review of the literature. Lung Cancer. 2005;47:385–394

PII: S0169-5002(10)00365-X

doi: 10.1016/j.lungcan.2010.07.005

Lung Cancer
Volume 72, Issue 1 , Pages 52-58 , April 2011

Article Tools

* Image Usage & Resolution